Envestnet Portfolio Solutions Inc. Lowers Holdings in Repligen Co. (NASDAQ:RGEN)

Envestnet Portfolio Solutions Inc. reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,443 shares of the biotechnology company’s stock after selling 73 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Repligen were worth $496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Resources Management Corp CT ADV purchased a new position in Repligen during the third quarter valued at $37,000. Quarry LP grew its position in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC bought a new position in Repligen during the fourth quarter valued at approximately $58,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Canaccord Genuity Group lifted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Royal Bank of Canada boosted their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $178.64.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Trading Down 2.2 %

Shares of NASDAQ RGEN opened at $141.95 on Wednesday. The business’s 50 day moving average price is $155.62 and its 200-day moving average price is $148.36. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $187.25. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market cap of $7.97 billion, a price-to-earnings ratio of -278.33, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.